John E. Monahan

13.2k total citations · 1 hit paper
18 papers, 1.6k citations indexed

About

John E. Monahan is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John E. Monahan has authored 18 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in John E. Monahan's work include Sarcoma Diagnosis and Treatment (4 papers), Cancer-related Molecular Pathways (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). John E. Monahan is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Cancer-related Molecular Pathways (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). John E. Monahan collaborates with scholars based in United States, Switzerland and Australia. John E. Monahan's co-authors include Richard W. Hanson, H Yoo-Warren, Michele A. Cimbala, David A. Ruddy, William R. Sellers, Daniel P. Rakiec, Wouter H. Lamers, Sunkyu Kim, Vesselina G. Cooke and Shivang Doshi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

John E. Monahan

18 papers receiving 1.5k citations

Hit Papers

An F876L Mutation in Androgen Receptor Confers Genetic an... 2013 2026 2017 2021 2013 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John E. Monahan United States 12 918 561 306 274 223 18 1.6k
Takako Asano Japan 27 1.3k 1.4× 412 0.7× 469 1.5× 378 1.4× 104 0.5× 84 2.1k
A Tompkins United States 13 893 1.0× 558 1.0× 512 1.7× 537 2.0× 108 0.5× 17 1.7k
Xuesong Ouyang United States 18 1.3k 1.4× 508 0.9× 333 1.1× 419 1.5× 204 0.9× 28 1.8k
Joseph M. Giaconia United States 11 801 0.9× 629 1.1× 242 0.8× 262 1.0× 206 0.9× 14 1.6k
Bekir Cinar United States 22 686 0.7× 424 0.8× 255 0.8× 223 0.8× 173 0.8× 29 1.3k
Takahito Hara Japan 24 757 0.8× 819 1.5× 430 1.4× 220 0.8× 347 1.6× 51 1.7k
G P Murphy United States 5 819 0.9× 1.0k 1.8× 276 0.9× 361 1.3× 290 1.3× 6 1.9k
Shanshan Bai China 20 1.3k 1.4× 716 1.3× 693 2.3× 480 1.8× 134 0.6× 51 2.1k
Ann M. McNulty United States 18 975 1.1× 452 0.8× 228 0.7× 435 1.6× 104 0.5× 33 1.7k
Luis J. Leandro‐García Spain 20 781 0.9× 322 0.6× 476 1.6× 532 1.9× 109 0.5× 31 1.5k

Countries citing papers authored by John E. Monahan

Since Specialization
Citations

This map shows the geographic impact of John E. Monahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Monahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Monahan more than expected).

Fields of papers citing papers by John E. Monahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Monahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Monahan. The network helps show where John E. Monahan may publish in the future.

Co-authorship network of co-authors of John E. Monahan

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Monahan. A scholar is included among the top collaborators of John E. Monahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Monahan. John E. Monahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Li, Fang, Hung Huynh, Xiaoyan Li, et al.. (2015). FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors. Cancer Discovery. 5(4). 438–451. 85 indexed citations
2.
Wang, Hui Qin, Jinsheng Liang, Ensar Halilovic, et al.. (2014). Abstract 2929: The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models. Cancer Research. 74(19_Supplement). 2929–2929. 1 indexed citations
3.
Korpal, Manav, Joshua M. Korn, Xueliang Gao, et al.. (2013). An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discovery. 3(9). 1030–1043. 425 indexed citations breakdown →
4.
Growney, Joseph D., Fang Li, Shumei Qiu, et al.. (2013). Abstract 1620: Dovitinib has anti-tumor activity in gastrointestinal stromal tumor (GIST) cell lines.. Cancer Research. 73(8_Supplement). 1620–1620. 1 indexed citations
5.
Porta, Diana Graus, Vito Guagnano, Christelle Stamm, et al.. (2012). Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials. Cancer Research. 72(8_Supplement). 854–854. 1 indexed citations
7.
Tiedt, Ralph, Pascal Furet, B.A. Appleton, et al.. (2011). A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research. 71(15). 5255–5264. 99 indexed citations
8.
Liu, Pixu, Hailing Cheng, Stephanie Santiago, et al.. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms. Nature Medicine. 17(9). 1116–1120. 210 indexed citations
9.
10.
Ito, Moriko, Louise Barys, Terence O’Reilly, et al.. (2010). Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis. Clinical Cancer Research. 17(3). 416–426. 86 indexed citations
11.
Jagani, Zainab, Dmitri Wiederschain, Alice Loo, et al.. (2010). The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells. Cancer Research. 70(13). 5528–5538. 48 indexed citations
12.
Buonamici, Silvia, Beatriz Muñoz, Jing Yuan, et al.. (2010). Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts. Cancer Research. 70(8_Supplement). 4290–4290. 4 indexed citations
13.
Schrader, Kasmintan A., Janine Senz, Alireza Heravi‐Moussavi, et al.. (2009). The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS ONE. 4(11). e7988–e7988. 71 indexed citations
14.
Firestone, Brant, Guizhi Yang, Hui Gao, et al.. (2009). Abstract B27: Correlation between TNFα and LCL161 anti-tumor activity in patient derived xenograft models of human cancer. Molecular Cancer Therapeutics. 8(12_Supplement). B27–B27. 11 indexed citations
15.
Yoo-Warren, H, John E. Monahan, John Short, et al.. (1983). Isolation and characterization of the gene coding for cytosolic phosphoenolpyruvate carboxykinase (GTP) from the rat.. Proceedings of the National Academy of Sciences. 80(12). 3656–3660. 189 indexed citations
16.
Cimbala, Michele A., et al.. (1982). Rapid changes in the concentration of phosphoenolpyruvate carboxykinase mRNA in rat liver and kidney. Effects of insulin and cyclic AMP.. Journal of Biological Chemistry. 257(13). 7629–7636. 179 indexed citations
18.
Suhadolnik, Robert J., et al.. (1977). Role of adenine ring and adenine ribose of nicotinamide adenine dinucleotide in binding and catalysis with alcohol, lactate, and glyceraldehyde-3-phosphate dehydrogenases.. Journal of Biological Chemistry. 252(12). 4125–4133. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026